Jiangsu Recbio Technology Co Ltd (2179)

Currency in HKD
7.45
-0.13(-1.72%)
Delayed Data·
2179 Scorecard
Full Analysis
Quickly burning through cash
2179 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
7.447.45
52 wk Range
6.769.80
Key Statistics
Bid/Ask
7.26 / 7.77
Prev. Close
7.58
Open
7.44
Day's Range
7.44-7.45
52 wk Range
6.76-9.8
Volume
1.5K
Average Volume (3m)
128.17K
1-Year Change
-5.13%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
2179 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Stock price often moves in the opposite direction of the market

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Jiangsu Recbio Technology Co Ltd Company Profile

Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People’s Republic of China. The company develops vaccines for the treatment of cervical cancers, and anal and genital warts, including REC603, a recombinant human papillomavirus (HPV) 9-valent vaccine that is in phase III clinical trial; REC601 and REC602 recombinant HPV bivalent vaccines targeting HPV type 6/11, which are in phase I clinical trials; REC604a, a recombinant HPV quadrivalent vaccine that is in pre-clinical stage; REC604c, a recombinant HPV 9-valent vaccine; and REC604a, a novel adjuvanted recombinant HPV quadrivalent vaccine. It also develops ReCOV, a recombinant bicomponent COVID-19 vaccine candidate that is in Phase II/III trial; REC610, a recombinant shingles vaccine that is in Phase l clinical trial; and REC617, a recombinant influenza quadrivalent vaccine that is in pre-clinical stage. In addition, the company’s vaccine pipeline consists of various pre-clinical stage products for respiratory diseases caused by respiratory syncytial virus (RSV)/ metapneumovirus infection, human cytomegalovirus disease, disease caused by hepatitis B virus infection, and herpes caused by herpes simplex infection. Jiangsu Recbio Technology Co., Ltd. was founded in 2011 and is headquartered in Taizhou, the People’s Republic of China.

Compare 2179 to Peers and Sector

Metrics to compare
2179
Peers
Sector
Relationship
P/E Ratio
−6.1x−19.8x−0.5x
PEG Ratio
−2.980.270.00
Price/Book
6.4x6.8x2.6x
Price / LTM Sales
125.7x21.9x3.3x
Upside (Analyst Target)
75.9%1.5%43.3%
Fair Value Upside
Unlock−17.6%6.9%Unlock

Earnings

Latest Release
Apr 22, 2025
EPS / Forecast
-0.64 / --
Revenue / Forecast
9.39M / --
EPS Revisions
Last 90 days

2179 Income Statement

FAQ

What Stock Exchange Does Jiangsu Recbio Technology Trade On?

Jiangsu Recbio Technology is listed and trades on the Hong Kong Stock Exchange stock exchange.

What Is the Stock Symbol for Jiangsu Recbio Technology?

The stock symbol for Jiangsu Recbio Technology is "2179."

What Is the Jiangsu Recbio Technology Market Cap?

As of today, Jiangsu Recbio Technology market cap is 3.71B.

What Is Jiangsu Recbio Technology's Earnings Per Share (TTM)?

The Jiangsu Recbio Technology EPS (TTM) is -1.16.

From a Technical Analysis Perspective, Is 2179 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Jiangsu Recbio Technology Stock Split?

Jiangsu Recbio Technology has split 0 times.

How Many Employees Does Jiangsu Recbio Technology Have?

Jiangsu Recbio Technology has 531 employees.

What is the current trading status of Jiangsu Recbio Technology (2179)?

As of 11 Aug 2025, Jiangsu Recbio Technology (2179) is trading at a price of 7.45, with a previous close of 7.58. The stock has fluctuated within a day range of 7.44 to 7.45, while its 52-week range spans from 6.76 to 9.80.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.